Michael L Birnbaum1,2,3,4, Sean D Cleary5, Claire Ramsay Wan6, Luca Pauselli7, Michael T Compton7. 1. The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York. 2. Lenox Hill Hospital, Department of Psychiatry, Northwell Health, New York, New York. 3. Hofstra Northwell School of Medicine, Hempstead, New York. 4. The Feinstein Institute for Medical Research, Manhasset, New York. 5. Milken Institute School of Public Health, Department of Epidemiology and Biostatistics, The George Washington University, Washington, District of Columbia. 6. Cambridge Health Alliance, Somerville, Massachusetts. 7. Department of Psychiatry, Columbia University College of Physicians & Surgeons, New York, New York.
Abstract
AIM: The Cannabis Experiences Questionnaire (CEQ) was developed to measure the subjective experiences of cannabis use both during and after intoxication. Despite the need to better understand the nature of the complex and significant relationship between cannabis use and early psychosis, this questionnaire has rarely been used in individuals with first-episode psychosis. METHODS: We conducted a set of factor analyses using CEQ data from 194 first-episode psychosis patients who used cannabis in order to uncover the underlying factor structure of the questionnaire and thus the overarching types of psychological experiences during/after using cannabis in young people with psychotic disorders. RESULTS: Our exploratory factor analysis identified 4 subscales, including: Distortions of Reality and Self-Perception (Factor 1), Euphoria Effects (Factor 2), Slowing and Amotivational Effects (Factor 3), and Anxiety and Paranoia Effects (Factor 4). CONCLUSIONS: Elucidating the underlying factor structure of the CEQ in first-episode psychosis samples could help researchers move towards a deeper understanding of the types of experiences associated with cannabis intoxication among young adults with first-episode psychosis and could inform the development of programs designed to reduce use, improve the course of illness, and possibly delay or prevent the onset of psychotic symptoms in those at risk.
AIM: The Cannabis Experiences Questionnaire (CEQ) was developed to measure the subjective experiences of cannabis use both during and after intoxication. Despite the need to better understand the nature of the complex and significant relationship between cannabis use and early psychosis, this questionnaire has rarely been used in individuals with first-episode psychosis. METHODS: We conducted a set of factor analyses using CEQ data from 194 first-episode psychosispatients who used cannabis in order to uncover the underlying factor structure of the questionnaire and thus the overarching types of psychological experiences during/after using cannabis in young people with psychotic disorders. RESULTS: Our exploratory factor analysis identified 4 subscales, including: Distortions of Reality and Self-Perception (Factor 1), Euphoria Effects (Factor 2), Slowing and Amotivational Effects (Factor 3), and Anxiety and Paranoia Effects (Factor 4). CONCLUSIONS: Elucidating the underlying factor structure of the CEQ in first-episode psychosis samples could help researchers move towards a deeper understanding of the types of experiences associated with cannabis intoxication among young adults with first-episode psychosis and could inform the development of programs designed to reduce use, improve the course of illness, and possibly delay or prevent the onset of psychotic symptoms in those at risk.
Authors: J Stirling; E J Barkus; L Nabosi; S Irshad; G Roemer; B Schreudergoidheijt; S Lewis Journal: Psychopathology Date: 2008-09-12 Impact factor: 1.944
Authors: Mary E Kelley; Claire Ramsay Wan; Beth Broussard; Anthony Crisafio; Sarah Cristofaro; Stephanie Johnson; Thomas A Reed; Patrick Amar; Nadine J Kaslow; Elaine F Walker; Michael T Compton Journal: Schizophr Res Date: 2016-01-17 Impact factor: 4.939
Authors: Michael T Compton; Mary E Kelley; Claire E Ramsay; Makenya Pringle; Sandra M Goulding; Michelle L Esterberg; Tarianna Stewart; Elaine F Walker Journal: Am J Psychiatry Date: 2009-10-01 Impact factor: 18.112
Authors: Stanley Zammit; Theresa H M Moore; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Br J Psychiatry Date: 2008-11 Impact factor: 9.319
Authors: F Bianconi; M Bonomo; A Marconi; A Kolliakou; S A Stilo; C Iyegbe; P Gurillo Muñoz; S Homayoun; V Mondelli; S Luzi; P Dazzan; D Prata; C La Cascia; J O'Connor; A David; C Morgan; R M Murray; M Lynskey; M Di Forti Journal: Psychol Med Date: 2015-12-16 Impact factor: 7.723
Authors: J M Stone; H L Fisher; B Major; B Chisholm; J Woolley; J Lawrence; N Rahaman; J Joyce; M Hinton; S Johnson; A H Young Journal: Psychol Med Date: 2013-05-24 Impact factor: 7.723
Authors: Luca Pauselli; Michael L Birnbaum; Beatriz Paulina Vázquez Jaime; Enrico Paolini; Mary E Kelley; Beth Broussard; Michael T Compton Journal: Schizophr Res Date: 2018-02-04 Impact factor: 4.939